Featured Research

from universities, journals, and other organizations

Study of new drug for vasculitis

Date:
August 26, 2013
Source:
University of Alabama at Birmingham
Summary:
A research consortium has shown that a new drug for vasculitis, a potentially life-threatening auto-immune disease which causes inflammation in blood vessels, is as effective as standard therapy over 18 months.

In a study published in the New England Journal of Medicine, a research consortium that includes the University of Alabama at Birmingham (UAB) has shown that a new drug for vasculitis, a potentially life-threatening auto-immune disease which causes inflammation in blood vessels, is as effective as standard therapy over 18 months.

While standard therapy consists of daily oral doses of a cancer drug called cyclophosphamide, followed by azathioprine, an immunosuppressant often used in organ transplant, researchers showed that four infusions of a monoclonal antibody called rituximab over one month were as effective in providing remission of symptoms as standard therapy in patients with types of vasculitis associated with anti-neutrophil cytoplasmic antibodies (ANCA).

Among patients receiving rituximab, 64 percent were in remission at six months, 48 percent at one year and 39 percent at 18 months, compared to 53 percent, 39 percent and 33 percent for standard therapy.

“The FDA approved rituximab for vasculitis based on our six-month data,” said Barri Fessler, M.D., associate professor of medicine in the UAB Division of Clinical Immunology and Rheumatology and one of the study co-authors. “We’ve now followed these patients for 18 months, and results indicate that rituximab continues to be as effective as standard therapy.”

Fessler said these findings give physicians a powerful new option for treating vasculitis, which, while rare, can lead to severe organ damage and even death.

“It provides flexibility for patients and physicians,” she said. “For some patients, rituximab may be the more appropriate medication. Now we have a choice.”

Fessler says rituximab works by targeting B cells which have been implicated in vasculitis. Rituximab decreases the number of B cells, which promotes remission of symptoms.

UAB was one of nine study sites for this trial, and Fessler says they will continue to follow the patients who participated in the trial to examine long term outcomes.

Vasculitis is made up of a family of conditions. The types of vasculitis studied in this trial included granulomatosis with polyangiitis and microscopic polyangiitis, both associated with ANCA. They are rare diseases, affecting 10-20 persons in a million.


Story Source:

The above story is based on materials provided by University of Alabama at Birmingham. Note: Materials may be edited for content and length.


Journal Reference:

  1. Ulrich Specks, Peter A. Merkel, Philip Seo, Robert Spiera, Carol A. Langford, Gary S. Hoffman, Cees G.M. Kallenberg, E. William St. Clair, Barri J. Fessler, Linna Ding, Lisa Viviano, Nadia K. Tchao, Deborah J. Phippard, Adam L. Asare, Noha Lim, David Ikle, Brett Jepson, Paul Brunetta, Nancy B. Allen, Fernando C. Fervenza, Duvuru Geetha, Karina Keogh, Eugene Y. Kissin, Paul A. Monach, Tobias Peikert, Coen Stegeman, Steven R. Ytterberg, Mark Mueller, Lourdes P. Sejismundo, Kathleen Mieras, John H. Stone. Efficacy of Remission-Induction Regimens for ANCA-Associated Vasculitis. New England Journal of Medicine, 2013; 369 (5): 417 DOI: 10.1056/NEJMoa1213277

Cite This Page:

University of Alabama at Birmingham. "Study of new drug for vasculitis." ScienceDaily. ScienceDaily, 26 August 2013. <www.sciencedaily.com/releases/2013/08/130826180511.htm>.
University of Alabama at Birmingham. (2013, August 26). Study of new drug for vasculitis. ScienceDaily. Retrieved September 19, 2014 from www.sciencedaily.com/releases/2013/08/130826180511.htm
University of Alabama at Birmingham. "Study of new drug for vasculitis." ScienceDaily. www.sciencedaily.com/releases/2013/08/130826180511.htm (accessed September 19, 2014).

Share This



More Health & Medicine News

Friday, September 19, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

The Cost of Ebola

The Cost of Ebola

Reuters - Business Video Online (Sep. 18, 2014) As Sierra Leone prepares for a three-day "lockdown" in its latest bid to stem the spread of Ebola, Ciara Lee looks at the financial implications of fighting the largest ever outbreak of the disease. Video provided by Reuters
Powered by NewsLook.com
What HealthKit Bug Means For Your iOS Fitness Apps

What HealthKit Bug Means For Your iOS Fitness Apps

Newsy (Sep. 18, 2014) Apple has delayed the launch of the HealthKit app platform, citing a bug. Video provided by Newsy
Powered by NewsLook.com
U.S. Food Makers Surpass Calorie-Cutting Pledge

U.S. Food Makers Surpass Calorie-Cutting Pledge

Newsy (Sep. 18, 2014) Sixteen large food and beverage companies in the United States that committed to cut calories in their products far surpassed their target. Video provided by Newsy
Powered by NewsLook.com
Residents Vaccinated as Haiti Fights Cholera Epidemic

Residents Vaccinated as Haiti Fights Cholera Epidemic

AFP (Sep. 18, 2014) Haitians receive the second dose of the vaccine against cholera as part of the UN's vaccination campaign. Duration: 00:34 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins